Source comparison
Best Thymosin Alpha-1 Supplier Third Party Tested 2026: Comparison
FDA 503B Facilities (Real Peptides sourcing) HPLC + mass spec + AAA at ISO 17025 labs (SGS, Eurofins) ≥98% by HPLC, molecular weight ±0.5 Da, sequence-verified AAA FDA-registered, biannual cGMP inspections, MedWatch reporting Full batch-to-vial traceability wi
This comparison does not assign a generated winner or score.
- FDA 503B Facilities (Real Peptides sourcing)
- HPLC + mass spec + AAA at ISO 17025 labs (SGS, Eurofins)
- ≥98% by HPLC, molecular weight ±0.5 Da, sequence-verified AAA
- FDA-registered, biannual cGMP inspections, MedWatch reporting
- Full batch-to-vial traceability with public FDA registry linkage
- Gold standard for reproducible research—every batch independently verified before release
- ISO-Certified Peptide Manufacturers
- HPLC + mass spec (AAA optional) at accredited third-party labs
- ≥95% by HPLC, molecular weight verified, sequence not always confirmed
- ISO 9001 quality systems, no FDA oversight
- Batch records maintained, third-party COA provided on request
- Reliable for most research applications; verify AAA inclusion if sequence fidelity is critical
- Grey-Market 'Research Chemical' Suppliers
- In-house testing or no COA provided
- Variable (often 85–92% actual vs ≥98% claimed)
- No regulatory oversight, self-reported standards
- Limited or non-existent—batch numbers may not link to verified records
- High risk of purity variance and sequence errors; unsuitable for publication-grade research
- Compounding Pharmacies (Non-503B)
- In-house HPLC (third-party optional, not standard)
- Typically 90–95% actual purity
- State pharmacy board oversight only, no FDA batch-level review
- Internal batch logs, may not include independent verification
- Adequate for non-critical applications; lacks the traceability and third-party verification required for multi-site studies